RecruitingNot Applicable

Autonomous Blood Drawing Optimization and Performance Testing

Denmark, Netherlands44,658 participantsStarted 2023-07-21

Plain-language summary

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device). The study consists of several phases (A, B1, B2, B3, C1, C2, C3, 0). Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing. Phases A, B2, B3, C1, C2, C3 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection). The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers can be included in a non-hospital site (Vitestro Site).

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • Age ≥16 years. Exclusion Criteria: * Unable to follow instructions, due to mental disability and/or incapacity * Unable to use device correctly due to physical impairment or disability (for example a patient with severe contractures or deformities) * No venipuncture possible in cubital fossa of both arms (for example: after amputation of both arms) * No venipuncture possible in cubital fossa due to contra-indications in both arms (for example: tattoos in both arms) * Incapacitated persons * Pregnant or breast-feeding The following contra-indications / exclusion criteria are respected per arm: * Arteriovenous fistula or vascular graft * Paretic or paralyzed arm (e.g. after stroke or trauma) * Infected skin in cubital fossa (for example: erysipelas or cellulitis) * Mastectomy side, axillary lymph node excised * Healed skin burns in cubital fossa * Edema in cubital fossa * Extensive scarring in cubital fossa * Hematoma in cubital fossa * Tattoos in cubital fossa In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2 or B3, venipunctures are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 and Phase B3 study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

First-time venipuncture success rate

Timeframe: Baseline

Trial details

NCT IDNCT05878483

SponsorVitestro B.V.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-12-31

Contact for this trial

Luuk Giesen, MD

+31 30 200 45 51 luuk.giesen@vitestro.com

View on ClinicalTrials.gov More Venipuncture trials